Condition: Triple Negative Breast Cancer · Sponsor: University of Chicago
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
This description comes directly from the study's public registry record.
Ilona Siljander · 773-834-6542 · isiljander1@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| Lagos State University Teaching Hospital | Ikeja, Lagos, Nigeria | Recruiting |
| Lagos University Teaching Hospital | Yaba, Lagos, Nigeria | Recruiting |
| Obafemi Awolowo University Teaching Hospitals Complex | Ile-Ife, Osun State, Nigeria | Recruiting |
| University of Ibadan Hospital | Ibadan, Oyo State, Nigeria | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06291064